This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.
ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization
by Zacks Equity Research
ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.
Here's Why You Should Hold on to LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.
Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study
by Zacks Equity Research
Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.
Merit Medical (MMSI) Expands Drainage Portfolio With New Product
by Zacks Equity Research
Merit Medical's (MMSI) new commercial product launch can make sample collection simple, safe and efficient.
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout
by Zacks Equity Research
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
BD's (BDX) New Offering to Boost Labs' Flow Cytometry Abilities
by Zacks Equity Research
BD's (BDX) latest product offering is expected to help improve access to instrumentation for complex scientific research to more laboratories.
Ecolab (ECL) Inks New Innovative Deal With Manchester United
by Zacks Equity Research
Ecolab (ECL) collaborates with Manchester United (MANU) to advance hygiene and sustainable practices across Old Trafford and the Carrington training ground.
Cooper Companies (COO) Unit's MiSight Gets Approval in China
by Zacks Equity Research
CooperVision, a unit of Cooper Companies (COO), receives approval for MiSight 1 day contact lenses from China's National Medical Products Administration for use in China.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum on the back of a solid product portfolio and improving margins. However, forex woes linger.
National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System.
Haemonetics (HAE) Q1 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Ongoing recovery in businesses, especially Hospital, and the initial Plasma Persona rollouts drove Haemonetics (HAE) fiscal first-quarter revenues.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up
by Zacks Equity Research
STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.
Zimmer Biomet (ZBH) Recovery Rate Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) sees slower recovery amid the emergence of a new strain of coronavirus in a number of markets, including Japan.
SmileDirectClub (SDC) Q2 Loss Wider Than Expected, Margin Up
by Zacks Equity Research
SmileDirectClub (SDC) registered year-over-year revenue growth in the second quarter, driven primarily by unique aligner shipment.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.
HSIC vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.